Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof

Patent metadata

Field	Value
Publication number	US-10392425-B2
Application number	US-201615549099-A
Country	US
Kind code	B2
Filing date	Feb 4, 2016
Priority date	Feb 5, 2015
Publication date	Aug 27, 2019
Grant date	Aug 27, 2019

Abstract

The present invention provides multivalent CD20-binding molecules, and compositions thereof, such as enriched compositions comprising large proportions of multivalent CD20-binding molecule relative to monovalent CD20-binding molecule. Certain multivalent CD20-binding molecules of the present invention comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptide regions derived from an A Subunit of a member of the Shiga toxin family. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for selective killing specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, tumors, and immune disorders. Certain multivalent CD20-binding molecules of the present invention, and compositions thereof, have uses for delivering agents into CD20-expressing cells, including for the intracellular labeling of CD20-expressing cells, collecting diagnostic information, and monitoring the treatment of variety diseases, such as cancers, tumors, and immune disorders which involve CD20-expressing cells.

First claim

The invention is claimed as follows:

1. A cytotoxic composition comprising:
a) a cytotoxic multivalent CD20-binding molecule, which multivalent CD20-binding molecule is multimeric and comprises or consists of at least two polypeptides linked by at least one covalent bond, each of said polypeptides having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55; wherein the cytotoxic multivalent CD20-binding molecule is capable of selectively killing a cell that expresses CD20 at a cellular surface; and
b) a monovalent CD20-binding molecule, wherein said monovalent CD20-binding molecule consists of a polypeptide having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55;

wherein the ratio of the monovalent CD20-binding molecule concentration to the total CD20-binding molecule concentration is less than 1:5.

2. The cytotoxic composition of claim 1 , wherein the ratio of the monovalent CD20-binding molecule concentration to the total CD20-binding molecule concentration is less than 1:11.

3. The cytotoxic composition of claim 2 , wherein the cytotoxic multivalent CD20-binding molecule is a dimer consisting of two of said polypeptides linked by at least one covalent bond, each having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55.

4. The cytotoxic composition of claim 3 , wherein the cytotoxic multivalent CD20-binding molecule is a homodimer consisting of two identical polypeptides linked by at least one covalent bond, each having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55.

5. The cytotoxic composition of claim 4 , wherein the multivalent CD20-binding molecule is a homodimer consisting of two identical polypeptides linked by at least one covalent bond, each having the amino acid sequence of SEQ ID NO: 54.

6. The cytotoxic composition of claim 4 , wherein the multivalent CD20-binding molecule is a homodimer consisting of two identical polypeptides linked by at least one covalent bond, each having the amino acid sequence of SEQ ID NO: 55.

7. The cytotoxic composition of claim 4 , wherein the ratio of said dimeric CD20-binding molecule concentration to total CD20-binding molecule concentration is greater than 3:4.

8. The composition of claim 7 , wherein the ratio of dimeric CD20-binding molecule concentration to total CD20-binding molecule concentration is greater than 7:8.

9. The cytotoxic composition of claim 2 , wherein the cytotoxic multivalent CD20-binding molecule is a higher-order multimer that comprises or consists of at least 3, 4, 5, or 6 of said polypeptides, each having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55; wherein at least two of said polypeptides are linked by at least one covalent bond.

10. The cytotoxic composition of claim 9 , wherein the cytotoxic multivalent CD20-binding molecule is a homomultimer that comprises or consists of at least 3, 4, 5, or 6 identical polypeptides, each having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55; wherein at least two of said polypeptides are linked by at least one covalent bond.

11. The cytotoxic composition of claim 10 , wherein the cytotoxic multivalent CD20-binding molecule is a homomultimer that comprises or consists of at least 3, 4, 5, or 6 identical polypeptides, each having the amino acid sequence of SEQ ID NO: 54; wherein at least two of said polypeptides are linked by at least one covalent bond.

12. The cytotoxic composition of claim 10 , wherein the cytotoxic multivalent CD20-binding molecule is a homomultimer that comprises or consists of at least 3, 4, 5, or 6 identical polypeptides, each having the amino acid sequence of SEQ ID NO: 55; wherein at least two of said polypeptides are linked by at least one covalent bond.

13. The cytotoxic composition of claim 3 , wherein, in addition to said dimer, the composition further comprises a cytotoxic multivalent CD20-binding molecule that is a higher-order multimer comprising or consisting of at least 3, 4, 5, or 6 polypeptides, each having at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 54 and SEQ ID NO: 55;
wherein at least two of said polypeptides are linked by at least one covalent bond; and
wherein the ratio of said higher-order multimer CD20-binding molecule concentration to total CD20-binding molecule concentration is less than 1:4.

14. The cytotoxic composition of claim 13 , wherein the ratio of said higher-order multimer CD20-binding molecule concentration to total CD20-binding molecule concentration is less than 1:7.

15. The cytotoxic composition of any one of claims 1 - 14 , wherein the at least one covalent bond comprises a disulfide bond.

16. The cytotoxic composition of claim 5 , wherein the disulfide bond involves a cysteine residue located at amino acid position 503.

17. The cytotoxic composition of claim 6 , wherein the disulfide bond involves a cysteine residue located at amino acid position 502.

18. The cytotoxic composition of any one of claims 1 - 14 , wherein administration of the cytotoxic composition to a first population of cells whose members are CD20 positive, and a second population of cells whose members are not CD20 positive, a cytotoxic effect of the cytotoxic composition to members of said first population of cells relative to members of said second population of cells is at least 3-fold greater.

19. The cytotoxic composition of any one of claims 1 - 14 and 16 - 17 , further comprising:
acetate, alcohol, alpha-tocopherol, aluminum monostearate, ascorbic acid, ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorobutanol, citrate, cysteine hydrochloride, dextrose, ethanol, ethylenediaminetetraacetic acid, ethyloleate, gelatin, glycerine, glycerol, lactic acid, lecithin, mannitol, methyl parabens, monostearate salt, organic ester, paraben, phosphate, phosphoric acid, polyalcohol, polyethylene glycol, polyol, propylene glycol, propylgallate, Ringer's solution, saline, sodium bisulfate, sodium bisulfite, sodium chloride, sodium metabisulfite, sodium sulfite, sorbitol, sugar, tartaric acid, or water.

20. The cytotoxic composition of claim 16 or claim 17 , further comprising:
citrate, polyalcohol, sorbitol, sugar, and water.

21. A pharmaceutical composition comprising
a cytotoxic composition according to any one of claims 1 - 14 and 16 - 17 , and
at least one pharmaceutically acceptable excipient, carrier, vehicle, aqueous carrier, nonaqueous carrier, solvent, buffer, alcohol, polyol, antioxidant, antimicrobial agent, isotonic agent, surfactant, chelating agent, stabilizer, adjuvant, preservative, wetting agent, emulsifying agent, dispersing agent, dispersion medium, coating, or adsorption delaying agent.

22. A pharmaceutical composition comprising
a cytotoxic composition according to any one of claims 1 - 14 and 16 - 17 , and
at least one pharmaceutically acceptable excipient or carrier comprising: acetate, alcohol, alpha-tocopherol, aluminum monostearate, ascorbic acid, ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorobutanol, citrate, cysteine hydrochloride, dextrose, ethanol, ethylenediaminetetraacetic acid, ethyloleate, gelatin, glycerine, glycerol, lactic acid, lecithin, mannitol, methy

Assignees

• Molecular Templates Inc

Inventors

• Poma Eric
• Willert Erin
• Kim Jason
• Higgins Jack
• Liu Jensing
• Flores-Lefranc Rodney

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/02

  specific for leukemia · CPC title